Exchange: NASDAQ·Updated 06:42 AM EDT
LNAI logo

LNAI Lunai Bioworks Inc.

$0.47
$0.002
(0.42%)
Pre-Market
Prev Close $0.472
EarningsNov 12
Mkt Cap$3.43M
Vol51,072.00

About LNAI

Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Sacramento, CA.
28

Bearish Sentiment

How do you feel about LNAI?

MarketForecasting
$LNAI .40 cents next week , I Wouldn’t rule out a bankruptcy proceeding , they historically have never turned a profit and never will . Lean short is my advice. Bankruptcy will give top holders all the spare change , not you . GLTA
1
MarketForecasting
$LNAI next stop is trading suspension , then delistment followed by going to otc , have fun trading this while it’s on the OTC .
MarketForecasting
$LNAI GEDi Cube B.V. went bankrupt and ceased operations , biosymetrics is on the verge of that as well. This is a well known scam .
Damotitan
$LNAI report filed before deadline, all as expected, no surprises. Updates on the court case and some non-dilutiive funding are what we need next
Stock_Catcher
$LNAI Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement

Advertisement|Remove ads.